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Purpose: To give a ﬁrst description of the perception of late effects among long-term survivors after
Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) and to validate the German Brief Illness
Perception Questionnaire (BIPQ).
Methods: This is a secondary analysis of data from the cross-sectional, mixed-method PROVIVO study,
which included 376 survivors from two Swiss HSCT-centres. First, we analysed the sample characteristics
and the distribution for each BIPQ item. Secondly, we tested three validity types following the American
Educational Research Association (AERA)Standards: content validity indices (CVIs) were assessed based on
an expert survey (n ¼ 9). A conﬁrmatory factor analysis (CFA) explored the internal structure, and cor-
relations tested the validity in relations to other variables including data from the Hospital Anxiety and
Depression Scale (HADS), the number and burden of late effects and clinical variables.
Results: In total, 319 HSCT recipients returned completed BIPQs. For this sample, the most feared threat
for post-transplant life was long lasting late effects (median ¼ 8/10). The expert-survey revealed an
overall acceptable CVI (0.82), three itemseon personal control, treatment control and causal represen-
tationeyielded low CVIs (<.78). The CFA conﬁrmed that the BIPQ ﬁts the underlying construct, the
Common-Sense Model (CSM) (c2 (df) ¼ 956.321, p ¼ 0.00). The HADS-scores correlated strongly with the
item emotional representation (r ¼ 0.648; r ¼ 0.656).
Conclusion: According to its overall content validity, the German BIPQ is a promising instrument to gain
deeper insights into patients’ perceptions of HSCT late effects. However, as three items revealed potential
problems, improvements and adaptions in translation are therefore required. Following these revisions,
validity evidence should be re-examined through an in-depth patient survey.
© 2017 Elsevier Ltd. All rights reserved.1. Introduction
Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) is
an intensive treatment for high-risk malignant as well as speciﬁcAPN), Anaesthesiology / Pain
CH-4031 Basel, Switzerland.
.life-threatening non-malignant haematological disorders and
certain genetic diseases (Tichelli et al., 2012). Although it is a
curative treatment, long-term survivors have an increased risk of
developing various adverse side effects, also known as late effects.
Because of their long-lasting character, late effects can be seen as
chronic illness conditions (Majhail and Rizzo, 2013; Stein et al.,
2008).
In addition to malignant late effects, e.g., solid tumours and
S. Valenta et al. / European Journal of Oncology Nursing 27 (2017) 17e2718secondary haematological diseases, HSCT recipients can also suffer
from non-malignant physical and psychological sequelae. Common
physical late effects include ocular, pulmonary, cardiac, endocrine,
skeletal, gastrointestinal and hepatic dysfunction (Gratwohl et al.,
2010; Socie et al., 2003). Among allogeneic HSCT recipients,
though, the major late complication is chronic Graft-versus-Host-
Disease (cGvHD), where donor T lymphocytes attack the patient's
organs. For the period from 2004 to 2007, the Center for Interna-
tional Blood and Marrow Transplant Research reported a 36%
incidence of cGvHD among HSCT recipients (Arai et al., 2015). Se-
vere forms of cGvHD can signiﬁcantly impact a patient's overall
health status, especially regarding functional impairment, activity
limitation, and pain (Ferrara et al., 2009; Majhail and Rizzo, 2013).
Additionally, the emotional burden can be immense: prolonged
psychological distress, including signiﬁcant levels of anxiety and
depression, is associated with worse post-transplant physical
health (Cooke et al., 2009; Syrjala et al., 2005). Patients already
suffering from high numbers of late effects are particularly dis-
tressed by the resulting exacerbation of psychological and physical
symptoms (Bhatia, 2011; Mosher et al., 2009).
In order to improve HSCT survivors' health-related quality of life,
it is important to enhance early detection of late affects (Khera
et al., 2011). Until now, the standard source of data concerning
post-HSCT late effects has been clinicians' reports. However, this
measure tends to underestimate the incidence, severity, and
distress of patients' perceived symptoms (Xiao et al., 2013).
Therefore, over the past decade, patient reported outcomes (PROs)
have been increasingly applied. As an umbrella concept, PROs
include parameters related to patients’ illness perceptions and their
self-reported health status (FDA, 2006).
Patients’ perceptions of illness conditions encompass their be-
liefs about their health problems and associated symptoms (Petrie
and Weinman, 2012). In this study, we rely on the deﬁnition of
illness representation set forth in the Common-Sense Model (CSM)
of self-regulatory theory. As Fig. 1 illustrates, the CSM assumes that
patients assess their health conditions based on cognitive and
emotional representations, adopt coping behaviours, estimate their
efﬁcacy, and ﬁnally appraise the outcomes (Cameron and
Leventhal, 2003; Leventhal et al., 1980).
Early research identiﬁed four dimensions of cognitive repre-
sentation that can be adapted to the experience of late effects as
chronic health conditions (Leventhal et al., 1984): perceived con-
sequences of outcomes; beliefs about the timeline (duration) of late
effects; the identity (label) associated with each late effect; and
causal reasons for late effects. Emotional representation is reﬂected
in the patient's concerns. Representations of coping procedures
include controllability, i.e., regarding regulation of personal and
treatment risks and beneﬁts, as well as the coherence of the health
threat (Broadbent et al., 2006; Leventhal et al., 2003).
So far, it is unknown how patients perceive post-HSCT late ef-
fects. By integrating the individual perceptions of a symptom or
illness, the self-regulatory theory of health threat cognition and
behaviour provides an appropriate basis to approach this question
(Leventhal et al., 1998). Based on the CSM of self-regulatory theory,
the Brief Illness Perception Questionnaire (BIPQ) provides an
appropriate PRO-measurement tool (Broadbent et al., 2006). Since
its publication in 2006, the questionnaire has been widely used in
populations suffering from various illness states. However, few
studies have applied the BIPQ to cancer patients, and no studies
have yet applied it to HSCT recipients. Evidence suggests that pa-
tients’ positive perceptions of their disease and side effects
accompany a clearer understanding of their illness and enhanced
self-management (Zivkovic et al., 2012). This sub-study of the
PROVIVO study was the ﬁrst to administer the German version of
the BIPQ in long-term survivors (Kirsch et al., 2015).Few studies have tested the validity of the BIPQ. This is prob-
lematic, given the fact that exploring the reliability and validity of a
measurement tool is a necessary precondition for a sound inter-
pretation of test scores (AERA et al., 2014; Frost et al., 2007).
Exploring the content validity of the Dutch BIPQ in a “think-aloud
study,” Van Oort et al. (2011) identiﬁed potential mis-
understandings in patients attending preoperative physiotherapy
exercise sessions. The BIPQ items on identity, personal control,
illness coherence, and causal representation revealed the most
difﬁculties. Another Dutch semantic evaluation including physio-
therapists and students rated the content validity as acceptable and
showed signiﬁcant correlations regarding four BIPQ-items
(p < 0.05) (De Raaij et al., 2012). In addition, Broadbent and col-
leagues conﬁrmed the English BIPQ’s strong concurrent (p < 0.001)
and predictive validity (p ¼ 0.03) in renal failure, diabetes, and
asthma samples (Broadbent et al., 2006). Until this study, the
German BIPQ had never been validated. Therefore, the purpose of
this study was to give a ﬁrst description of the perception of late
effects among long-term survivors after HSCT and to explore the
validity of the German BIPQ.
2. Methods
2.1. Design, sample, and setting
This is a sub-study of the cross-sectional, mixed-method PRO-
VIVO study. Details of that study's methods have been published
elsewhere (Kirsch et al., 2015; NCT01275535). In brief, data were
collected from November 2011 to October 2012 from a convenience
sample of 376 patients attending the University Hospitals Basel and
Zurich outpatient clinics following HSCT. Ethical approval was
provided by the ethics committees of Beider Basel (the Cantons of
Basel-Stadt and Basel-Land) (EKBB) and Zurich (KEK Zürich). Par-
ticipants had received an allogeneic HSCT more than one year
before, were 18 years or older, and were able to understand and
read German. Participants were excluded if they suffered from
psychiatric illness, illiteracy, or terminal illness, or were currently
hospitalized for acute care. Before receiving the BIPQ to complete,
patients were asked whether they were suffering from any late
effects (“yes or no”). Only participants suffering from some form of
late effects (marked with “yes”) and who answered at least seven of
the nine BIPQ items were included in our analysis.
2.2. Variables and measurement
2.2.1. Patient reported outcomes
The Brief Illness Perception Questionnaire (BIPQ) assesses re-
spondents’ cognitive and emotional illness representation of any
health condition based on the CSM of self-regulatory theory
(Broadbent et al., 2006; Leventhal et al., 1998). The BIPQ was
developed on the basis of the Illness Perception Questionnaire
(IPQ). A revised and extended version of the questionnaire (IPQ-R)
includes more than 80 items on a multifactorial Likert-type scale
approach (Moss-Morris et al., 2002; Weinman et al., 1996). The
original 9-item BIPQ uses a single-item scale approach on a
continuous linear scale. Items 1 to 8 are interval scaled, applying
11-point (0e10) Likert-type scales for consequences, timeline, per-
sonal control, treatment control, identity, coherence, concern, and
emotions. Higher scores reﬂect more threatened perceptions of late
effects.
Item 9 is an open question asking the respondent to list the
three most important reasons for developing late effects. The
general version of the questionnaire uses the word “illness”, which
must be replaced in each item with the name of the examined
health condition - in this case “late effects”
Fig. 1. The Common-Sense Model (CSM) of Leventhal's self-regulatory theory.
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the original English into 24 different language versions, all of which
are available on the Illness Perception Questionnaire Website
(Weinman et al., 2012).
The Hospital Anxiety and Depression Scale (HADS). Anxiety and
depression symptomatology were assessed via the HADS, which
consists of two subscales and 14 items using 4-point Likert-type
scales (Zigmond and Snaith, 1983). The two subscales, one
measuring anxiety, the other depressive symptomatology, consist
of seven items each. Scores of 11 ormore on either subscale indicate
signiﬁcant psychological morbidity; those between 8 and 10
represent borderline cases; and those below 8 are clinically insig-
niﬁcant. Both subscales can be interpreted independently (Bjelland
et al., 2002).2.2.2. Clinical data
Clinical data provided by clinicians on each patient include years
after transplantation, grade of cGvHD according to the National
Health Institute (NIH) criteria (none, mild, moderate, severe)
(Pavletic et al., 2006), and a Karnofsky Performance Status Scale
(KPS) index. Based on a criteria related performance index of
physical ability, the KPS index rates individual health and well-
being from 100% (normal function) to 10% (moribund) (Mor et al.,
1984).
Observable late effects rated by the physician. In accordance with
the Common Terminology Criteria for Adverse Events (CTCAE)
version 3.0 (NCI, 2006), physicians assessed the cumulative inci-
dence and severity of patients’ late effects at the time of the annualcheck-up. Thirteen general late effects affecting various organs
were rated according to their occurrence and severity: thyroid
dysfunction, osteoporosis, osteonecrosis, cardiac dysfunction, pul-
monary function disorder, renal and liver dysfunction, ocular
problems, hearing problems, dental/mouth problems, iron over-
load, neurotoxicity, neurocognitive disorders, and secondary
malignancy.
The cumulative number of late effects per patient was assessed,
ranging from 0 to 13. The severity of each was rated from 0 (non-
existent) to 4 (disabling or life-threatening), resulting in a possible
total score of 0e52. Considering the number and severity of late
effects, the CTCAE speciﬁes ﬁve categories of burden of late effects:
none (no late effects as present); mild (late effects of severity grade
1 only; 3 late effects); moderate (one or more late effects grade 2;
or 4e6 late effects); severe (one or more late effects grade 3; or 7
late effects) and disabling (one or more late effects grade 4 irre-
spective of number of late effects).2.3. Statistical analysis
All analyses were performed using IBM SPSS Statistics, version
22.
Aim 1: descriptive statistics. We begin with an overview, using
descriptive statistics, of the sample's characteristics and each BIPQ
item's distribution. Following the BIPQ analysis instructions, we
reversed the scores of items 3, 4 and 7 so that they measured in the
same direction as the others. For the open question on causal rep-
resentation (item 9), we followed Broadbent's advice and
S. Valenta et al. / European Journal of Oncology Nursing 27 (2017) 17e2720categorized the patients' statements as pre-treatment, psycholog-
ical burden or physical reasons (Broadbent, 2006).
Aim 2: psychometric testing of the BIPQ. Validity testing of the
BIPQ followed the American Educational Research Association (AERA)
Standards (AERA et al., 2014). Thus, we tested three distinct aspects
of validity: test content, internal structure, and relations to other
variables. Evidence based on response process and consequences of
testingwere not addressed in the present study, since these validity
types are more relevant in the context of evaluating educational
and employment questionnaires (AERA et al., 2014). All questions
on research (R), hypotheses (H), and the thorough assessment of
the validity evidence regarding the BIPQ can be found in Table 1.
Evidence based on test content (R 1 & 2, Table 1) was assessed
using input from an interdisciplinary group of experts consisting of
nine nurses and physicians from three German and two Swiss
transplantation centres, each of whom had worked at least two
years in post-HSCT patient follow-up care. On 4-point Likert-type
scales ranging from 1 (not comprehensible) to 4 (highly compre-
hensible), these experts rated the comprehensibility of each BIPQ
item. Based on their ratings, we calculated a content validity index
for each item (I-CVI) and an overall scale-content validity index (S-
CVI) for the entire questionnaire. The I-CVI was computed as the
number of experts giving a rating of either 3 or 4 (dichotomizing
the ordinal scale into relevant and not relevant), divided by the
total number of experts. The S-CVI was computed using the average
approach (S-CVI/Ave) for all items on the scale. Therefore, we
summed up the I-CVI and then divided it by the number of items.
An I-CVI of  0.78 and an S-CVI  0.80 can be regarded as satis-
factory (Polit and Beck, 2006; Polit et al., 2007). The experts were
also asked for feedback and suggestions for improvement of the
questionnaire. In addition to the expert survey, we analysed the
number of missing values for each BIPQ item.
Evidence based on internal structure (R3, Table 1) required a
conﬁrmatory factor analysis (CFA). To produce this, we tested
whether the internal components of the BIPQ ﬁt the underlying
construct of the Common-Sense Model (CSM) of self-regulatory
theory. All eight interval-scored BIPQ-items were included in this
analysis. Following the CSM, we applied a two-factor-model: one
factor depicted the cognitive and emotional representation; the other
the coping procedures. Considering Kaiser's rule, we included only
factors with eigenvalues greater than 1 in our interpretations
(Fabrigar et al., 1999). To test our sampling adequacy, we used the
Kaiser-Meyer-Olkin Index, which should be greater than 0.5 (Kaiser
and Rice, 1974). Analysing the factorability of the correlation matrix
required Bartlett's test of sphericity (p < 0.05). We considered
loading factors greater than 0.4 as acceptable (Field, 2009).
As expressed in hypotheses 1 to 5 (Table 1), evidence based on
relations to other variableswas assessed to explore criterion-related
validity. The mean subscale scores of the German BIPQ were
therefore correlated with other clinical variables acknowledged for
their relationships to late effects: HADS score, cGvHD severity,
Karnofsky Performance Status Scale (KPS) index, and the number
and burden of late effects. Depending on the distribution charac-
teristics, we estimated Pearson's r or Spearman's r (two-tailed-
tests).
3. Results
3.1. Study sample
Of the 376 patients participating in the PROVIVO study, 319
(85%) fulﬁlled the criteria for inclusion in our analysis, i.e., they
reported late effects and completed at least 7 of the 9 BIPQ items
(Fig. 2). Table 2 summarizes the participants’ characteristics: pa-
tients were predominantly male (57.1%), with a mean age of 50.2years (SD ¼ 12.9), and a median post-SCT follow-up period of 7.3
years (IQR ¼ 8.9). Nearly half (46.7%) had received a HSCT against
acute myeloid (31.7%) or acute lymphatic (15.0%) leukaemia. Most
experienced either no cGvHD (51.1%) or a mild form (28.5%), and
77.1% were highly functional (KPS index scores  90%). With
respect to HADS scores, 6.3% showed high anxiety levels, i.e. their
anxiety subscale scores were above the cut-off-point of 8.
Regarding the depression subscale, 4.1% reported depressive
symptoms. Most experienced a mild to moderate (47.6%) burden of
late effects. Two participants suffered from disabling late effect
burdens, impairing their quality of life dramatically.
3.2. Descriptive analysis of the BIPQ-items
Table 3 displays the average scores of the BIPQ items. The second
item, timeline, showed the highest score, meaning that patients
perceived their late effects as long-term threat (median ¼ 8,
IQR ¼ 7). The items on consequences and identity (items 1 and 5:
median ¼ 3, IQR ¼ 4), comprehension (item 7: median 2, IQR ¼ 4)
and emotional representation (item 8: median¼ 2, IQR¼ 5) received
relatively low scores. The items on personal and treatment control
(item 3 and 4) and on concerns (item 6) received moderate scores
(median ¼ 5, IQR ¼ 5) indicating that participants were concerned
about their late effects and their controllability.
Regarding the categorization of item 9 (the open question), re-
spondents perceived medication intake (54%), chemotherapy (45%)
and irradiation (41%) as the most important reasons for developing
late effects. Also, patients perceived psychological burdens (36%),
the HSCT (23%) and cGvHD (17%) as further reasons for developing
post-HSCT late effects (see Fig. 3).
3.3. Validity testing
3.3.1. Content validity
The BIPQ's S-CVI/Avewas acceptable, at 0.82.With respect to the
I-CVIs, six itemseconsequences, timeline, identity, concerns,
comprehension, and emotional representationeshowed high values
ranging from 0.78 to 1.0 (possible range: 0.0e1.0). However, the
remaining three e personal control, treatment control, and causal
representation e yielded I-CVIs below the recommended minimum
of 0.78 (see Table 3).
According to our experts' feedback, some items would beneﬁt
from small adaptions: concerning the question on the duration of
late effects (item 2, timeline), four experts noted that one more time
speciﬁcation would improve this item's comprehensibility. With
respect to controllability (items 3 and 4), ﬁve experts mentioned
that the term “control” invites misunderstandings. Suggested im-
provements included replacing “control” with “inﬂuence” or
“manage” since some late effects like cGvHD are difﬁcult to put
under control (German: „beeinﬂussen” oder „verbessern”). Five ex-
perts also indicated that item 7, comprehension of late effects, re-
quires further explanation. Two experts suggested the following
amendments: “How well do you feel the treatment of your late effects
is explained to you?” (German: “Wie gut fühlen Sie sich über die
Behandlung der Sp€atfolgen aufgekl€art?”). Item 8, on emotional rep-
resentation, was described as a “confusing question,” as it includes
only negative feelings. It was suggested that simpliﬁcation would
promote understanding: “How strongly are your feelings inﬂuenced
by your late effects?” (German: “Wie stark sind Ihre Gefühle durch die
Sp€atfolgen beeinﬂusst?”). To promote a fuller grasp of causal repre-
sentation (item 9), two experts suggested shortening the question
and inserting examples such as “medication or therapy.”
For the interval-scaled items (1e8), a missing value analysis
yielded comparatively low values (range: 0%e5.6%, see Table 3).
Regarding causal representation (item 9), 22% of respondents
Table 1
Research questions (R) and hypotheses (H) of the validation study.
Lines of validity evidence Research question (R) or hypotheses (H) Analysis
Evidence based on test
content
R1: Are the BIPQ items relevant and appropriate? Expert survey to assess the Content Validity
Index (CVI)
R2: Are the BIPQ items clear and easy to understand? Missing value analysis
Evidence based on
internal structure
R3: Do the internal components of the BIPQ ﬁt the deﬁned construct? Conﬁrmatory Factor Analysis (CFA)
Evidence based on
relations to other
variables
H1: Patients with anxiety and/or depression report a higher degree of consequences,
chronic timeline, identity, concern and emotional representations of late effects
(Gruber et al., 2003; Mosher et al., 2009).
Estimating correlations between BIPQ items
1e8 and corresponding variables from the
PROVIVO study
H2: A higher number of late effects is associated with a higher grade of emotional
and cognitive representation (Pallua et al., 2010).
Anxiety & depression (HADS)
H3: A higher burden of late effects indicates higher reporting on cognitive and
emotional representations as well as lower perceived controllability of late effects
(Leventhal et al., 1998).
Severity of cGvHD (Grade 0e4)
H4: Higher severity of cGvHD is associated with higher ratings for cognitive and
emotional representations of late effects (Lee et al., 2006; Lee et al., 2003).
Functional status (Karnofsky Performance
Status Scale Index)
H5: A lower score of the Karnofsky Performance Status Scale Index is associated
with higher cognitive and emotional representation of late effects (Sorror et al.,
2008).
Number and burden of late effects (CTCAE)
Note. Tabulated research questions and hypotheses to test the lines of validity evidence based on the AERA-Standards for psychometric testing (AERA et al., 2014).
Fig. 2. Flow Chart of included participants.
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3.3.2. Internal structure
The Kaiser-Meyer-Olkin measure of sampling adequacy (0.77)
and Bartlett's test of sphericity (c2 ¼ 956.321, p ¼ 0.00) indicated
that the data were appropriate to conduct a CFA. The results of the
CFA were consistent with the CSM's underlying concept: all items
loaded above the recommended minimum level ( > 0.4) on the two
expected factors, i.e., (1) cognitive and emotional representation and
(2) coping procedures. These two factors accounted for 62.67% of the
total variance.
Factor loadings ranged from 0.498 to 0.906 (see Fig. 4). All items
loaded strongly and consistently on the two expected factors. The
only exception was timeline (item 2) which cross-loads positively
on the ﬁrst (0.498) and negatively on the second (-0.378). Never-
theless, the internal components of the BIPQ ﬁt the underlying
construct of the CSM very well.
3.3.3. Relations to other variables
Table 4 shows positive correlations between the respondents'
anxiety and depression scores and the BIPQ consequences, timeline,
identity, concern, and emotional representation items. Ashypothesized (H1), emotional representation correlated strongly
with scores for anxiety (r ¼ 0.648, p < 0.01) and depression
(r ¼ 0.656, p < 0.01). However, regarding the second hypothesis
(H2), a high number of late effects correlated only marginally with
consequences (r ¼ 0.214, p < 0.01), identity (r ¼ 0.219, p < 0.01), and
concerns (r ¼ 0.154, p < 0.01). As can be seen in Table 4, our third
hypothesis (H3) also had limited support: we found low correla-
tions between burden of late effects and the corresponding BIPQ
items; and contrary to the expectations reﬂected in the fourth (H4)
and ﬁfth (H5) hypotheses, cGvHD scores and the KPS Index showed
only weak to moderate correlations with the BIPQ items on con-
sequences, identity, concern and emotional representations (see
Table 4).
4. Discussion
This was both the ﬁrst study to evaluate the German BIPQ in
relation to long-term survivors’ perceptions of post-HSCT late ef-
fects and the ﬁrst to measure its psychometric properties following
the new AERA standards (AERA et al., 2014). Our analyses indicated
that HSCT recipients perceive long-lasting late effects-and the
accompanying suffering-as their greatest therapy-related threat.
Table 2
Characteristics of the study sample (n ¼ 319).
Characteristic Total sample, n ¼ 319
Gender; female, n (%) 137 (42.9)
Age in years, median (SD; range) 50.2 (12.9; 19e76 years)
Years after HSCT, median (IQR; range) 7.3 (8.9; 1e33 years)
Diagnosis, n (%)
AML 101 (31.7)
ALL 48 (15.0)
CML 52 (16.3)
CLL 12 (3.8)
Plasma Cell disorder 17 (5.3)
Hodgkin or Non-Hodgkin lymphoma 38 (11.9)
Myelodysplastic syndrome 24 (7.5)
Myeloproliferative syndrome 10 (3.1)
Non-malignant haematologic disease 17 (5.3)
Chronic GvHDa, n (%)
None 163 (51.1)
Mild 91 (28.5)
Moderate 35 (11.0)
Severe 11 (3.4)
Not documented 19 (6.0)
KPS Indexb, n (%)
100%e90% 246 (77.1)
<90%e80% 31 (9.7)
<80% 19 (6.0)
Not documented 23 (7.2)
Anxietyc, n (%)
No anxiety-borderline 299 (93.7)
Indication of anxiety 20 (6.3)
Depressionc, n (%)
No depression-borderline 305 (95.9)
Indication of depression 13 (4.1)
Observable late effectsd, n (%)
Number of late effects, median 2.0
Burden of late effects
none 64 (20.1)
mild 84 (26.3)
moderate 68 (21.3)
severe 101 (31.7)
disabling 2 (0.6)
Note. Selected characteristics of the HSCT survivor sample focusing on variables of
this sub-study.
Abbreviations IQR¼ Interquartile Range, AML ¼ Acute Myeloid Leukaemia,
ALL ¼ Acute Lymphatic Leukaemia, CML¼Chronic Myeloid Leukaemia, CLL¼Chronic
Lymphatic Leukaemia, cGvHD ¼ chronic Graft-versus-Host-Disease, KPS¼ Karnof-
sky Performance Status Scale.
a Chronic GvHD was rated by the physician according to the cGvHD grading
scheme recommended by the National Institutes of Health consensus development
project on criteria for clinical trials in cGvHD (Pavletic et al., 2006).
b Karnofsky Performance Status Scale (KPS) Index of physical ability (Mor et al.,
1984).
c Anxiety and depression measured by the Hospital Anxiety and Depression Scale
(HADS) (Bjelland et al., 2002).
d Observable late effects rated by the physician, CTCAE version 3.0 (NCI, 2006).
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validity and gave some hints for improvement of the German
translation. Furthermore, a CFA indicated that the internal com-
ponents of the BIPQ ﬁt the underlying construct of the Common-
Sense Model of self-regulatory theory. Regarding relations to
other variables, along with the HADS scores, the number and
burden of late effects correlated signiﬁcantly with individual BIPQ
items. However, the clinical variables, among others, correlated
moderately at best with the BIPQ.4.1. Descriptive analysis of the BIPQ responses
The timeline item showed the highest scores (median ¼ 8,
Q1 ¼ 3, Q3 ¼ 10), indicating that patients recognize the chronic
nature of their late effects. The literature indicates that late effects
can occur at any time after treatment andmay last the remainder ofthe patient's life (Majhail and Rizzo, 2013). However, compared to
the duration of late effects, patients rated concern and emotional
representation relatively low, suggesting that many consider their
physical constraints manageable (Mosher et al., 2009; Syrjala et al.,
2004).
Surprisingly, patients rated consequences low (median: 3),
indicating a belief that their late effects would have no serious
consequences. They also felt capable of bringing them under per-
sonal and treatment control (median: 5). In contrast to these results,
the meta-analytic review of the CSM published by Hagger and
Orbell (2003) showed that patients with benign chronic disease
who emphasized a chronic timeline also typically indicated a lack of
controllability, experienced serious consequences, and attributed a
strong identity to their health condition.
Our ﬁndings in the survivor population might be explained by a
so-called ‘‘response shift‘‘. Patients may adapt their internal stan-
dards or values and use this new approach to determine their
perceptions of illness burden. Regarding this type of post-HSCT
adjustment, supportive care, optimism and ﬂexible expectations
are excellent examples of helpful mechanisms and attitudes
(Beeken et al., 2011; Sprangers and Schwartz, 1999).
Nearly 50% of patients indicated the treatment process itself
(e.g., chemotherapy, medication, and irradiation) as the most
important cause of post-HSCT late effects, which is consistent with
the scientiﬁc view of their aetiology (Tichelli et al., 2012). Risk
factors for developing late post-HSCTcomplications depend on pre-
treatment procedures, the details of the conditioning regime, and
the use of total body irradiation. Also, while more than a third of
respondents (36%) connected their psychological burden to
evolving late effects, the causality is unclear. I.e., questions remain
as to whether various post-HSCT late effects arise from psycho-
logical burden or the post-HSCT psychological burden intensiﬁes
existing late effects. Both may be true. Research indicates both that
distressing post-HSCT physical and cognitive side effects accom-
pany psychological burden (Herzberg et al., 2013; Mosher et al.,
2009), and that elevated depressive symptoms correlate with
reduced physical function and decreased survival in HSCT re-
cipients (Loberiza et al., 2002; Rusiewicz et al., 2008).
4.2. Validity testing
4.2.1. Content validity
A strong overall content validity index (0.82) conﬁrms that the
BIPQ's sample of items is sufﬁcient to represent the construct of
interest, i.e., patients' perceptions of post-HSCT late effects. With
respect to the I-CVI, though, the items “personal and treatment
control” indicated potential problems: experts reported that these
were formulated too vaguely, and that their use of the term “con-
trol” could lead to misunderstandings. Previous research has also
shown that the “personal and treatment control” items assume that,
based on pre-existing knowledge, the respondents' can regulate the
risks and beneﬁts of their behaviour (Cameron and Leventhal,
2003). Therefore, as suggested by Van Oort et al. (2011), it was
decided that “control” should be replaced with “inﬂuence".
Likewise, the “causal representation” items showed a low I-CVI
(0.63). They were also missing a high number of patient responses
(22%), indicating potential difﬁculties in answering. This explana-
tion would support the ﬁndings of Van Oort et al. (2011), who
illustrated patients’ difﬁculties in answering items on “identity”,
“comprehension”, “control” and “causal representation” of a chronic
illness (Van Oort et al., 2011). Again, in accordance with Van Oort
et al. (2011), our experts suggested replacing “control” with
“inﬂuence”.
Similarly, the “causal representations'” item (item 9) was
improved by reframing the question from “Please list in rank-order
Table 3
BIPQ-item characteristics.
BIPQ-items Missing data (%) Mean (SD)a Median
(IQR)
I-CVI-Index
1. Consequences 0% 3.45
(3.00)
3 (4) 0.89
2. Timeline 5.6% 6.30
(3.80)
8 (7) 0.89
3. Personal control 2.5% 5.53
(3.16)
5 (5) 0.56
4. Treatment control 2.5% 5.19
(3.41)
5 (6) 0.56
5. Identity 0.3% 3.36
(3.01)
3 (4) 1.00
6. Concern 0.3% 3.43
(2.94)
5 (5) 1.00
7. Comprehension 1.6% 3.08
(2.93)
2 (4) 0.89
8. Emotional representation 0.3% 3.91
(2.98)
2 (5) 0.78
9. Causal representation 22% not applicable 0.63
Note. Descriptive statistics for the individual items of the BIPQ. Frequencies for included participants only (n ¼ 319). Item 3, 4 and 7 were reversed prior to analysis.
An I-CVI  0,78 is regarded as satisfactory (Polit and Beck, 2006).
Abbreviations: SD¼Standard Deviation, IQR¼Interquartile range, I-CVI¼Item Content Validity Index.
a Mean scores of BIPQ-items: Higher scores reﬂect a more threatening view of late effects.
Fig. 3. Patients' reasons for having late effects: Descriptive analysis of BIPQ item 9.
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illness?” to “What do you think caused your illness”? (Van Oort
et al., 2011). Such modiﬁcations should be guided by cognitive
patient debrieﬁng, as it is considered the gold standard for the
development and modiﬁcation of PRO instruments (Cella et al.,
2007; Patrick et al., 2011).4.2.2. Internal structure
The CFA revealed that the internal components of the BIPQ ﬁt
the underlying construct, which consisted primarily of cognitive
and emotional representation, and secondly of coping procedures.
The timeline itemwas an exception as it loaded positively (0.498) on
the ﬁrst and negatively (-0.378) on the second factor. A possible
explanation for these factors' cross-loading can be found in the
meta-analytic review of the CSM, which showed that, even while
patients' perceptions of an illness chronicity can correlatesigniﬁcantly with more cognitive and emotional consequences,
they can also correlatewith coping strategies such as avoidance and
denial (Hagger and Orbell, 2003). For instance, faced with pro-
longed late effects, e.g., severe cGvHD, the individual can create a
cognitive and/or emotional representation based on their current
experience of symptoms. At the same time, perceptions of long-
lasting cGvHD effects can hinder recovery, as patients may lose
hope and not try to develop coping strategies or otherwise self-
manage their condition (Hagger and Orbell, 2003; Pallua et al.,
2010).
The three items on personal control, treatment control, and
comprehension were strongly associated with the second factor,
coping procedures. Cameron and Leventhal (2003) also strongly
correlated the controllability of a disease-i.e., the patient's sense of
empowerment regarding coping behaviours or treatment efﬁcacy-
with individuals' coping procedures (Hagger and Orbell, 2003).
Fig. 4. Factor loadings of the Conﬁrmatory Factor Analysis.
Table 4
Relations to other variables: results of calculated coefﬁcients.
Variables HADS-scores Late effects Clinical variables
Item 1e8 of
the BIPQ
Anxiety Score Depression Score Number of late effects Burden of late effects Grade of cGvHD KPS-Score
Consequences 0.363** 0.590** 0.214** 0.143* 0.256** -0.331**
Timeline 0.195** 0.270** 0.050 0.077 0.088 -0.055
Personal control (reversed scores) 0.038 0.052 0.061 0.057 0.039 0.097*
Treatment control (reversed scores) 0.025 0.063 0.081 0.125* 0.102* 0.032
Identity 0.413** 0.609** 0.219** 0.151** 0.270** -0.336**
Concerns 0.522** 0.539** 0.154** 0.124* 0.172** -0.171**
Comprehension (reversed scores) 0.011 0.092 0.010 0.083 0.069 0.096*
Emotional representation 0.648** 0.656** 0.083 0.091 0.128** 0.218**
Note. Asterisks denote statistical signiﬁcance: **p < 0.01 level, *p < 0.05 level. The choice of the correlation coefﬁcient depends on the level of measurement: All correlations
between BIPQ-items and HADS-scores and late-effects are Pearson r. Those between BIPQ-items and the clinical variables are Spearman rho. Item 3, 4 and 7 were reversed
prior to analysis, N ¼ 319.
Abbreviations: HADS¼ Hospital Anxiety- and eDepression-Scale, cGvHD ¼ chronic Graft-versus-Host-Disease, KPS¼ Karnofsky Performance Status Scale.
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tributes to individuals' coping processes by enhancing their self-
management abilities (Armoogum et al., 2013; Majhail and Rizzo,
2013). This suggests that long-term post-HSCT survivors who
perceive that their late effects are controllable and understandablewould rely more on problem-focused cognitive and emotional
strategies and social support to cope with their symptom man-
agement than would those who ﬁnd their conditions incompre-
hensible and perceive that they cannot inﬂuence their outcomes
(Hagger and Orbell, 2003; Solber Nes et al., 2013).
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Correlations between the BIPQ and HADS (anxiety and depres-
sion) scores supported our ﬁrst hypothesis (H1): more threatening
views of late effects were associated with higher anxiety and
depression symptomatology. This correlation supports Hagger and
Orbell's ﬁnding that individuals suffering from psychological
distress perceive more serious consequences, expect their symp-
toms to continue longer (timeline), and identify more strongly with
consequences (Hagger and Orbell, 2003). However, regarding our
four remaining hypotheses (H2eH5), the number and burden of
late effects as well as the clinical variables correlated only weakly
with the BIPQ items. These weak correlations very likely resulted
from the characteristics of our sample: the majority of participants
were highly functional (KPS index score 90%), experienced no
cGvHD symptoms (51.1%), and suffered from no serious late effects
(67.7%).
4.3. Limitations
The ﬁndings of this descriptive and validation study must be
interpreted in the context of its potential limitations. First, this
study gives only a ﬁrst description of the patients’ perception of late
effects after HSCT. Further research is needed to provide in-depth
descriptive analyses concerning differences among age groups,
educational strata and how patient characteristics mediate the
relation between the BIPQ values and the clinical variables.
Second, we only assessed the German BIPQ's content validity via
feedback from clinicians. A patient survey would have yielded a
more reliable rating of its content validity as a PRO measurement.
Third, with regard to the small segment of our sample suffering
from severe forms of late effects, this sampling bias very likely
skewed the validity measurement in relations to other variables.
Gathering more knowledge regarding the relationship between
clinical and demographic variables and the BIPQ items in HSCT
recipients will require further studies. Fourth, this version of the
German BIPQ, for use among long-term post-HSCT survivors, asks
not about particular illnesses (e.g., cGvHD), but about late effects in
general. This general formulation may have made it more difﬁcult
for respondents to express their perceptions of speciﬁc late effects.
Finally, we did not test for reliability. Future studies should explore
the German BIPQ's reliability in long-term post-HSCT survivors.
4.4. Recommendations for clinical practice and future research
implications
Our study showed that the German BIPQ can be easily scored
and interpreted, making it particularly useful for clinical applica-
tions. However, after its wording has been modiﬁed-based on pa-
tient cognitive debrieﬁng-further pilot-testing in real-life settings
will be necessary to conﬁrm its feasibility and clinical relevance:
patient surveys using focus groups or in-depth interviews could
help considerably to understand patients' difﬁculties with the in-
strument (Basch and Abernethy, 2011; Patrick et al., 2011).
Additionally, further research will be necessary to identify
whether these difﬁculties and misinterpretations could be avoided
by replacing the general term “late effects” with a particular late
effect, such as cGvHD. Based on these revisions and reﬁnements,
the German BIPQ's psychometric properties need to be reassessed
in a randomly selected sample of HSCT recipients. Majhail et al.'s
descriptive analysis of the BIPQ (2012) reveals that long-lasting late
effects are experienced as very stressful. As state-of-the-art follow-
up guidelines suggest, these should be tackled individually in
clinical practice (Majhail et al., 2012).
Also, long-term surviving HSCT recipients depend on systematic
long-term follow-up to maintain their symptom management andcoping strategies (Haggstrom and Doebbeling, 2011). Not only
these survivors, but also their spouses and other caregivers exhibit
high levels of psychological distress. Therefore, a regular family-
centred, symptom-based approach to perceived post-HSCT psy-
chological and physical burdens, i.e., a self-management program
focusing on long-term survivors’ late effects, should be incorpo-
rated into long-term follow-up to identify and manage late effects
of cancer and its treatment (Majhail et al., 2012; McCabe et al.,
2013). However, provision of self-management support will
require funding at the health system level. To date, however, as no
appropriate payment system exists for such support in ambulatory
HSCT settings, many clinicians have difﬁculty offering adequate
counselling for patients and their families. Ideally, innovative
nurse-led programs could include regular nursing counselling,
patient and family education with consistent information, and
monitoring of treatment side-effects (Armoogum et al., 2013;
Kurtin et al., 2013).
5. Conclusion
This study has shown that the BIPQ can deepen our knowledge
of long-term post-HSCT survivors' perceptions of late effects. Pro-
longed symptoms were perceived as the most threatening view of
late effects. In agreement with previous research, participants
indicated that they considered the treatment process itself the
most important reason for developing late effects.
All three types of validity were satisfactory for the question-
naire. (1) Our expert survey revealed an acceptable overall content
validity, with only three items requiring further reﬁnement; (2) a
conﬁrmatory factor analysis showed that the internal structure of
the questionnaire ﬁts the underlying construct of the CSM; and (3)
strong correlations between individual BIPQ items and clinical
variables supported its validity evidence.
Still, before it can be used in long-term post-HSCT survivors,
further research is needed to reﬁne the German BIPQ with respect
to our results and to re-examine the psychometric properties of the
reﬁned version via patient surveys.
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